Hiroshi Mohri
Overview
Explore the profile of Hiroshi Mohri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
2095
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Strizki J, Gaspar J, Howe J, Hutchins B, Mohri H, Nair M, et al.
Antimicrob Agents Chemother
. 2023 Dec;
68(1):e0095323.
PMID: 38047645
Molnupiravir, an oral prodrug of N-hydroxycytidine (NHC), previously demonstrated broad antiviral activity against multiple RNA viruses and has shown a high barrier to the development of resistance. Here, we present...
2.
Liu L, Casner R, Guo Y, Wang Q, Iketani S, Chan J, et al.
Immunity
. 2023 Sep;
56(10):2442-2455.e8.
PMID: 37776849
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities against the virus, we screened serum samples from convalescing COVID-19...
3.
Wang Q, Guo Y, Zhang R, Ho J, Mohri H, Valdez R, et al.
Lancet Infect Dis
. 2023 Sep;
23(10):e397-e398.
PMID: 37708906
No abstract available.
4.
Duan Y, Zhou H, Liu X, Iketani S, Lin M, Zhang X, et al.
Nature
. 2023 Sep;
622(7982):376-382.
PMID: 37696289
Nirmatrelvir is a specific antiviral drug that targets the main protease (M) of SARS-CoV-2 and has been approved to treat COVID-19. As an RNA virus characterized by high mutation rates,...
5.
Wang Q, Yeh A, Guo Y, Mohri H, Yu J, Ho D, et al.
Emerg Microbes Infect
. 2023 May;
12(1):2210237.
PMID: 37132357
The SARS-CoV-2 Omicron subvariants have dominated the pandemic due to their high transmissibility and immune evasion conferred by the spike mutations. The Omicron subvariants can spread by cell-free virus infection...
6.
Liu L, Casner R, Guo Y, Wang Q, Iketani S, Chan J, et al.
bioRxiv
. 2023 Apr;
PMID: 37090592
SARS-CoV-2 continues to evolve and evade most existing neutralizing antibodies, including all clinically authorized antibodies. We have isolated and characterized two human monoclonal antibodies, 12-16 and 12-19, which exhibited neutralizing...
7.
Iketani S, Mohri H, Culbertson B, Hong S, Duan Y, Luck M, et al.
Nature
. 2022 Nov;
613(7944):558-564.
PMID: 36351451
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been demonstrated to be clinically useful against COVID-19 (refs. ). However, because SARS-CoV-2 has evolved to become resistant to...
8.
Wang Q, Li Z, Ho J, Guo Y, Yeh A, Mohri H, et al.
Lancet Infect Dis
. 2022 Nov;
22(12):1666-1668.
PMID: 36328002
No abstract available.
9.
Charness M, Gupta K, Stack G, Strymish J, Adams E, Lindy D, et al.
N Engl J Med
. 2022 Sep;
387(11):1045-1047.
PMID: 36069968
No abstract available.
10.
Iketani S, Mohri H, Culbertson B, Hong S, Duan Y, Luck M, et al.
bioRxiv
. 2022 Aug;
PMID: 36032976
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been demonstrated to be clinically useful in reducing hospitalization or death due to COVID-19 . However, as SARS-CoV-2 has...